SEC Form 4 · accession 0001578563-18-000015
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Patrick J Crutcher
Officer — VP, Business Development
Period of report
Sep 25, 2018
Accepted (ET)
Sep 27, 2018 · 4:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534120
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 25, 2018 | A | 1,645,286 | — | A | 1,645,286 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Received in exchange for 1,000,000 shares of Ichorion Therapeutics, Inc. common stock in connection with the merger of Ichorion Therapeutics, Inc. into the Issuer. On September 25, 2018 the closing price of the Issuer's common stock was $4.55 per share.